Resano A, Prieto I, Sanz M L, Oehling A
Department of Allergology and Clinical Immunology, Faculty of Medicine, University of Navarra, Pamplona, Spain.
J Investig Allergol Clin Immunol. 1995 Sep-Oct;5(5):289-93.
The histamine release test has been proven to be a very useful method for in vitro diagnosis of IgE-mediated allergy to inhalant and food allergens, as well as for the immunotherapy follow-up of the allergic patient. The aim of the present study was to assess the influence of the degree of sensitization in allergic patients sensitive to Dermatophagoides pteronyssinus on their dose-response curves in histamine release tests. To achieve this aim, we studied 109 D. pteronyssinus allergic patients and 25 healthy control subjects. Intracutaneous skin test, D. pteronyssinus-specific and total IgE quantitations, and histamine release tests were carried out in all the patients. In the case of the histamine release test, five D. pteronyssinus extract concentrations were used (2822.5, 282.25, 28.22, 2.82 and 0.28 UBE/ml), and two patterns of histamine release in sensitive patients were found: one with maximal histamine release at the highest antigen concentration (group I) and the other with maximal release attained at lower concentrations (group II). A sensitization score was designed, after the results from specific IgE and intracutaneous skin tests. There were significant differences (p < 0.05) in antigen-specific and total IgE levels, and in papule diameters and sensitization scores, between the control group and groups I and II. Both groups showed significantly higher (p < 0.05) histamine releases than the control group in response to anti-IgE antibodies. When stimulating the cells with anti-IgE antibodies, histamine release in group II was higher than in group I, although this difference was not significant. Finally, the best correlation between sensitization score and antigen-specific histamine release was found at the 2.82 UBE/ml concentration (r = 0.84, p < 0.001).
组胺释放试验已被证明是体外诊断对吸入性和食物过敏原的IgE介导过敏以及对过敏患者进行免疫治疗随访的一种非常有用的方法。本研究的目的是评估对尘螨过敏的过敏患者的致敏程度对其组胺释放试验剂量反应曲线的影响。为实现这一目的，我们研究了109名尘螨过敏患者和25名健康对照者。对所有患者进行了皮内皮肤试验、尘螨特异性和总IgE定量以及组胺释放试验。在组胺释放试验中，使用了五种尘螨提取物浓度（2822.5、282.25、28.22、2.82和0.28 UBE/ml），并在敏感患者中发现了两种组胺释放模式：一种在最高抗原浓度下组胺释放最大（I组），另一种在较低浓度下达到最大释放（II组）。根据特异性IgE和皮内皮肤试验结果设计了一个致敏评分。对照组与I组和II组之间在抗原特异性和总IgE水平、丘疹直径和致敏评分方面存在显著差异（p<0.05）。两组在抗IgE抗体刺激下均显示出比对照组显著更高（p<0.05）的组胺释放。在用抗IgE抗体刺激细胞时，II组的组胺释放高于I组，尽管这种差异不显著。最后，在2.82 UBE/ml浓度下发现致敏评分与抗原特异性组胺释放之间的最佳相关性（r = 0.84，p<0.001）。
